tnx-102 sl news - Search News

Tonix, fibromyalgia and New Drug Application

FDA accepts Tonix’s NDA for non-opioid fibromyalgia drug TNX-102 SL

Tonix Pharmaceuticals Holding Corp. (Nasdaq: TNXP) announced that the US Food and Drug Administration (FDA) has accepted its New Drug Application (NDA) for TNX-102 SL, a non-opioid, centrally acting analgesic designed for fibromyalgia management.

Business Insider · 22h

Tonix Pharmaceuticals Announces FDA Acceptance of the New Drug Application (NDA) for TNX-102 SL for Fibromyalgia

FDA is expected to assign a Prescription Drug User Fee Act (PDUFA) target action date and announce whether Priority Review has been granted in

MarketWatch · 21h

Tonix Pharmaceuticals Gets FDA Review of Fibromyalgia Drug

Tonix Pharmaceuticals Holding said the Food and Drug Administration has accepted its application seeking approval of its TNX-102 SL product candidate for the chronic pain condition fibromyalgia.

18h

What's Going On With Tonix Pharmaceuticals Stock Today?

Tonix Pharmaceuticals Holding Corp (NASDAQ: TNXP) shares are trading lower Tuesday after initially jumping after the company ...

Monthly Prescribing Reference16h

FDA to Review Sublingual Cyclobenzaprine for Fibromyalgia Management

The Food and Drug Administration (FDA) has accepted the New Drug Application (NDA) for TNX-102 SL (cyclobenzaprine HCL sublingual tablets) for the management of fibromyalgia.

21h

Tonix Pharma’s TNX-102 SL Nears FDA Approval Milestone

Tonix Pharma ( (TNXP) ) has provided an announcement.

Tonix Pharmaceuticals Reports Third Quarter 2024 Financial Results and Operational Highlights

Submitted New Drug Application (NDA) to FDA for TNX-102 SL for fibromyalgia based on two statistically significant Phase 3 ...

19h

This Micro Cap Is Getting Bid Up Prior To Opening Bell

Charting, Price Performance, News & Related Contracts.

Results that may be inaccessible to you are currently showing.

Hide inaccessible results

Tonix, fibromyalgia and New Drug Application

Related topics